Keytruda

This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.

Merck bulks up in cancer with $2.2bn Peloton buy

Merck bulks up in cancer with $2.2bn Peloton buy

It ties in with CEO Ken Frazier’s pledge to make bolt-on acquisitions to bolster Merck’s internal R&D as it starts to look beyond immuno-oncology powerhouse Keytruda ... Keytruda is already making waves in RCC, having been approved for first-line RCC

Latest news

More from news
Approximately 121 fully matching, plus 192 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year.

  • Is China ready for a pharmaceutical gold rush?

    Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels. ... In light of recent clinical data, Keytruda is widely regarded as the better of the two checkpoint inhibitors in lung cancer.

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.